



## Updated Phase 1 Clinical Trial Monotherapy Data for IDE196 in Metastatic Uveal Melanoma to be Presented at AACR Conference

March 29, 2019

SOUTH SAN FRANCISCO, Calif., March 29, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that Novartis will present a poster with data from an ongoing clinical trial evaluating the tolerability and preliminary clinical activity of IDE196 as a potential monotherapy in metastatic uveal melanoma (MUM).

IDE196, coded LXS196 by Novartis, is a potent small molecule protein kinase C (PKC) inhibitor which IDEAYA plans to develop for the treatment of cancers with GNAQ and GNA11 mutations. Notably, approximately 90% of metastatic uveal melanoma patients harbor activating mutations in GNA11 or GNAQ.

Novartis is conducting an ongoing Ph1 clinical trial, entitled "*A Phase I, multi-center, open-label, study of LXS196, an oral protein kinase C inhibitor, in patients with metastatic uveal melanoma*" (ClinicalTrials.gov Identifier: NCT02601378). In the ongoing trial, IDE196 is being studied as a single-agent and in combination therapy with HDM201, Novartis' human double minute 2 (HDM2) inhibitor, an important negative regulator of the [p53](#) tumor suppressor.

The IDE196 poster will be presented on April 1, 2019 as follows:

**Session Title:** Phase I Clinical Trials: Part 2

**Session Date and Time:** Monday Apr 1, 2019 8:00 AM - 12:00 PM

**Session Location:** Georgia World Congress Center, Exhibit Hall B, Poster Section 17

**Poster Board Number:** 25

IDEAYA Biosciences, Inc. has an exclusive license from Novartis for further clinical development of IDE196, together with unrestricted rights to commercialize worldwide.

### About IDEAYA Biosciences

IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates extensive capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies. We are applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets. For additional information, please visit [www.ideayabio.com](http://www.ideayabio.com).